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The Conditions of and Requirements for the 
Formation of Clusters in Biotechnology
In this article, with the help of the value chain model, I explain the functioning of biotech clusters. The 
“cluster” phrase was originally defined by Porter. In my opinion, the problem with Porter’s and other classical 
definitions of a cluster is that they are static, whereas the main feature of clusters’ is actually their dynamic 
nature. This is the reason why the following should also be included in the definition:
– clusters emerge in a turbulent way: processes cannot be foreseen due to the lack of linearity. 
– a cluster, however, is a kind of an arena, because dense and changing vertical input-output relations and 
connections between horizontal organizations always generate a sort of a need for change. 
– clusters cause changes in the innovation policy, as they support the evolution of a policy which is 
appropriate for cluster formation. That is, they act as catalysts for the formation of better conditions. 
Accordingly, Porter’s original definition needs modification.
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In biotechnology, as in other innovative, high-tech industries, changes in knowledge level, 
paradigms, and projects, are very rapid. In regards to biotech project costs, minimizing 
risk is essential for business organizations. They usually fulfill this requirement through the 
division of labour. 
In this article, with the help of the value chain model (Porter 1998), I explain the 
functioning of biotech clusters. I describe the main tasks completed during biotechnology 
pharmaceutical manufacturing and division of labour generally applied in the sector. 
Business organizations were forced to cooperate due to the tendency of transformation 
within the sector, the extension of tasks, and the increasing costs. One type of this 
cooperation is called clustering. 
The main features of cluster functioning are dynamics, feedback, and a great number of 
interactions, which cannot be explained by the traditional value chain model. The value 
chain model was intended to be made more dynamic by illustrating the feedback.
According to Porter, regional clusters are geographic concentrations, based on the 
innovative relation network of a particular field’s competing and cooperating companies, 
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associated and supporting branches, financial institutes, providing and cooperating 
infrastructural (background) institutes (education, research), and entrepreneur alliances 
(chambers, professional associations). (Steiner 1998, Lengyel 2001, Porter 1985, Porter 1998, 
Porter 2000).
In red biotechnology1, this means a project-based interconnection of pharmaceutical 
companies, biotech companies, R+D organizations (universities, research institutes), and 
other advisory organizations. 
In my opinion, the problem with Porter’s and other classical definitions of a cluster is 
that they are static, whereas the main feature of clusters’ is actually their dynamic nature. 
This is the reason why the following should also be included in the definition:
– clusters emerge in a turbulent way: processes cannot be foreseen due to the lack of 
linearity. 
– a cluster, however, is a kind of an arena, because dense and changing vertical input-
output relations and connections between horizontal organizations always generate a sort 
of a need for change. 
– clusters cause changes in the innovation policy, as they support the evolution of 
a policy which is appropriate for cluster formation. That is, they act as catalysts for the 
formation of better conditions. Accordingly, Porter’s original definiton needs modification.
There are several theories describing the motivations for cooperation. I will use the value 
chain model, which is popular in the pharmaceutical industry, to describe the operation 
of clusters. The problem with this model is that it is static, meaning feedback dynamisms, 
so characteristic in biotechnology, are missing. I will try to fill it in, based on my practical 
experience.
Biotechnology and pharmaceutical companies
Medical biotechnology is used by two main types of companies. They are either large 
companies drawing on a long history in the given field and developing into more and more 
innovative biotechnology users, such as large pharmaceutical companies (“big pharma”). 
Or, modern biotechnological companies emerge, which the previously stated large 
companies purchase knowledge, projects or services from. Mainly the large companies 
control the biotechnology industry with regard to revenue. However this does not lead 
to strict adherence to traditions and the conservation of states of power. This is because, 
in terms of knowledge and the number of innovative projects, altogether small biotech 
companies have the comparative advantage. 
Many biotech companies were founded in the 70-s and 80-s. First they sought to 
become completely vertically integrated companies, encompassing everything from R&D 
to production and sales. They used closed innovation only. Gradually, these companies 
brought new trends in their innovation strategies. At first the companies lacked two things 
that kept them from reaching their goals: the lack of funds, and experienced managers. 
However these two things are essential (in addition to technology) for a company to grow 
from a spin-off enterprise to a large pharmaceutical company. The classic pharmaceutical 
companies, being on the top that time, already possessed these resources. Thus some of 
1 Red biotechnology is applied to medical processes. Some examples are the designing of organisms to produce 
antibiotics, and the engineering of genetic cures through genetic manipulation.
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them purchased biotech companies while others however were not open to biotechnology 
in terms of investment and cooperation (Murray 2002).  
The volume and complexity of biotech and pharmaceutical projects grew in relation 
to the amount of available information and acquired knowledge in an environment of 
steadily growing needs for new knowledge. This placed further emphasis on cooperation, 
the sharing of costs and risks of producing new R&D results. An industry of high risk – 
high benefit type emerged. This led to problems, but opportunities as well. Concerning the 
problems it was asked: Who will finance the costs of research? Will investors think that 
the industry is too risky? Naturally the significance of professional investors and specific 
tenders increased with this. 
Companies were forced to cooperate due to the high risk associated with biotechnology, 
the complexity of strategic management rules and the then unusually high amount of 
needed funds. First of all, the necessary monetary tools are available only at the largest 
companies. Second, the necessary competencies are often missing with smaller companies. 
For example, a smaller company, a market leader in R&D, does not have the necessary 
experience either of the capability needed to clinical testing or production. Cooperation 
is necessary to fill these gaps. With this sharing of different sorts of risks will be realised. 
These risks, actually non-calculable uncertainties several times, may be technology, market, 
regulatory or competition related. The later reflects on the segments of all the other risks, 
since the rapid development of China, South Korea and India. The only advantages can 
only be quality and knowledge for the traditional pharma producing countries. But 
precisely these are areas where China and India are developing rapidly, while maintaining 
the seemingly natural price advantage. Europe and the USA can only compete with these 
products if they do not count on price advantage, but on therapeutic advantage. This means 
producing a newer, better molecule, first of all. However this larger added intellectual value 
brings larger risks on behalf of technological, market and registration. These tendencies are 
also catalysts of cooperation. 
It is precisely these different, yet interrelated risks that make pharmaceutical biotechnology 
complex. To successfully manage complex processes and instability necessitates cooperation. 
Instabilities are cross-linked, they can even strengthen or weaken each other. An example 
of mutual strengthening is the technological uncertainty of producing a new molecule, 
and the registration and legalization which follow. Registration gives the same molecule an 
added economical value and can, if it is registered already, decrease market instability, since 
it can become a market leader, a so called “blockbuster”2, with multi million dollar yearly 
turnover. 
Thus instabilities constitute a kind of synergic system. Instabilities are difficult to predict 
individually, their interrelations are even more so. 
2 A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year.
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Figure 1:
A typical time-schedule of a new biotech identity
(based on (DeBresson-Hu 1999) composed by the author)
Necessity of cooperation can be explained from another point of view as well (figure 
1). Validity period of a patent is 20 years from the date of application, which, in case of 
pharmaceuticals can be extended by at most 5 years (SPC3). According to Figure 1, the 
product generally appears on the market 13-15 years after the patent application. With the 
end of the patent period, one must also count with the appearance of generic and biosimilar 
products.4 Thus there is, at most 10, but more often only 5 years to cover the entire costs 
of R&D and clinical costs and make some revenue. Thus everyone seeks to make the time 
needed for R&D as short as possible. One method could be some sort of open innovation, 
which supports cooperation and outsourcing instead of solving everything in-house. There 
are numerous factors which make a part of the R&D earlier fully integrated in the vertical 
control target of outsourcing. To shorten the needed time to find a molecule and make it 
a drug, the steeply growing costs of keeping all the needed expertise within the firm, the 
decreasing costs of reaching the needed expertise outside, together the transaction costs 
3 SPC means supplementary protection certificates. SPCs were introduced by the SPC Regulation to improve the 
protection afforded to innovations in the pharmaceutical sector. SPC is designed to compensate for the reduction 
in effective patent life caused by delays in the regulatory approval process and will give up to five years’ additional 
protection beyond the life of the patent or 15 years from the date of the first marketing authorisation, whichever is less.
4 A generic drug (generic drugs, short: generics) is a drug which is produced and distributed without patent protection. 
The generic drug may still have a patent on the formulation but not on the active ingredient.
Biosimilars or follow-on biologics are terms used to describe officially approved new versions of innovator 
biopharmaceutical products, following patent expiry.
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arguments and the abundance of expertise outside are all for giving advantage to trust R&D 
tasks to outsiders who are already experts in the given field. This method definitely saves 
time and possibly costs as well and systematically open access to better solutions than those 
available in a “closed innovation” method. 
Naturally, in this case, different interests collide. The interest of the originator company 
as they are called in the pharma industry is to hold on its monopole status as long as 
possible. This is exactly opposite to the interests of the generic companies, who would 
like to appear on the market as soon as possible. Consumers are located between the 
two parties, thus favouring an intermediate approach. They profit from the appearance 
of generic pharmaceuticals in two ways. Their appearance leads to a decrease in prices, 
while at the same time, the original companies have to develop new pharmaceuticals, which 
will be protected from the generic companies for a while. A too short patent period is not 
good for the consumers, as in this case it will not be profitable for originator companies 
to produce new pharmaceuticals, or the testing period will not be long, thorough enough, 
leading to potential hazards. 
The structure of biotechnology clusters
Interest groups were formed between geographically proximate business and other 
organizations through comprehensive, shared projects. The associations can be formal, 
or informal. There can be distant or close bonds. In knowledge-based branches, research 
organizations such as universities, research institutions, and spin-off companies can also 
become part of these networks. Due to global competition, successful company models were 
born, relying on the spatial concentration, in other words, the local grouping (clustering), 
of advantages. The central concept of the interaction is that the creation of a powerful local 
branch becomes preferable (especially in technological sectors) in which (Presidis 1999):
•	 the output (added value) is increasing,  
•	 the number of employees is rising,
•	 the chances for the survival of the enterprise are better, thus it can stand its ground 
against global competition,
•	 it improves the competitiveness of the region (salaries, work output, employment),
•	 the number of people in the given field exceeds the critical mass, thus providing 
economical strength.
The company sphere is trying to react upon environments with rapidly changing dynamics 
with developing radical innovations, while they are aware of the fact that they have to 
make high stakes decisions on a very unstable knowledge base. Usually, there is a complex, 
multidimensional, nonlinearly interacting instability around the radical innovation, the 
solution of which often requires cross-linked steps. In terms of management, it is important 
to emphasize that, unlike small innovations, the managing ability of radical innovations 
involves the navigating ability which is necessary when unpredictable events unexpectedly 
happen. As for innovations, we should apply the approach of evolutionary economy. We 
make models considering variations, selective media, niche, and active adaptations.
In our globalizing world, due to the more and more frequently formed „close interactions” 
(they are „close” because of the strength of interaction), the medium is often turbulent; it is 
characterised by the occurrence of an unsteady state in both small or large areas. 
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During this process the previously latent needs of consumers develop into needs which 
determine production technology/product in the system of interactions, which are realized 
in coevolution. Of course, trends also emerge. They, nevertheless, are generally shorter and 
more conditional than in earlier historical eras. (Hronszky - Várkonyi 2006)
The companies realized, that by relying on local background, or local business partners, 
they could survive in a very competitive global environment. Furthermore, they can not 
only just survive, they are capable of becoming more adaptable and of increasing their 
income as well (Swann - Preveze 1996). In general, the profitability of companies operating 
in clusters increases by 2-4 %, and the survival rate of small and mid size companies is 
much higher than for individually operating enterprises. (Domonkos 2007)
Basically, there are two possible methods for cooperation. One gives stability and the other 
innovation. The two types of cooperation require different institutional structures, since 
the cooperation is for a different purpose. In different branches of industry, associations, 
which in this case are clusters, form for different reasons. In biotechnology, they are formed 
primarily to aid innovation, whereas in the furniture industry they are formed to stabilize 
the current state.  
Figure 2.:
The structure of a typical biotech cluster composed by the author5
As we can see in figure 2, the core of the biotechnological cluster is formed by research 
institutions and universities. Biotechnological enterprises from different areas are grouped 
around this core, since their most important input is knowledge, or new information. Spin-
off companies are important members of the group. By using the knowledge generated 
5 CRO means Contract Research Organization
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at universities, new spin-off companies are formed, and start-up companies are founded. 
Some of them generate new investments, as a result bridging the gap between academic 
and industrial sectors. Thus, the key to the dynamism of the cluster is the spin-off and 
innovation oriented start-up companies. However, the cluster is necessary for their 
successful operation, because, due to their small size and lack of funds, without their 
input knowledge from universities, industrial relations, and the funding from investors, 
they cannot complete the innovation. Cooperation between different sectors and support 
from service (trade) oriented companies, financial institutions, government authorities and 
foreign partners (other clusters) is necessary for the successful operation of a cluster.
If we look at the same group based on economic power and the flow of funds (Figure 3.), 
then the cluster is centered around its industrial partners, which are the pharmaceutical 
and biotech companies. They form the core of the cluster, meaning they lead the cluster, 
and since the product will enter the market under their names, they have market goals, 
ideas, and they sense market needs and possibilities. They bear a significant part of the 
financial and knowledge related resources necessary for operation as well. The academic 
sectors in the given industry are grouped around them, providing the knowledge, which is 
not present in the core of the cluster. 
Figure 3.:
The structure of a typical biotech cluster group based on economic
power and the flow of funds (created by the author)
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The proper functioning of clusters requires that the operation of the different organizations 
be in tune with the structure of the group. It is important that new members become 
involved in the organization, and that existing organizations provide new members with 
space and functionality. This is also in their best interest. New solutions and organizations 
must be compatible with existing ones, but not the same. They must contribute something 
new. 
There can be several different solutions: formal associations may form through mergers, 
purchases or joint companies. These do not threaten clusters, because in the USA for 
example, formal and informal associations can work side by side. 
In practice, clusters grew out of different backgrounds, for different reasons. There are 
different methods for their development and support. A certain percentage of clusters, 
especially in developed countries arose spontaneously through self-organization. 
There is no formal relationship between companies competing with each other. So, the 
representatives of a locally strong, yet innovative industry form a voluntary cooperation, 
to share the costs and risks of research and development. This cooperation is much more 
difficult to formalize than artificially generated clusters. So in many cases it is difficult 
to determine which companies belong to a cluster, since this can change from project to 
project. However, cluster development policies, the improvement of an industrial branch 
and tenders aimed at cluster formation, all catalyze the process of cluster formation. In the 
case of these artificially produced clusters, it is important that they become self sufficient, 
meaning that the initial support should only function as an incentive to speed up the start-
up process.  
Operation of biotechnological clusters through
(biotechnological) value chain
According to Porter, a regional cluster is some sort of geographic concentration, based on 
the innovative cooperation of competitive companies, supporting industries, financial 
institutions, service and cooperative infrastructure (background) institutions (education, 
research), and business associations (chambers, professional unions) (Porter 1985, Porter 
1998). In my opinion, the problem with Porter’s definition and other classic cluster-
definitions is that they are static, whereas, the most important characteristics of clusters, is 
their dynamic nature. Thus it is best to include the following in the definition: 
– The formation of a cluster is a turbulent process: the processes are unforeseeable, the 
absence of linearity excludes perspective. 
– At the same time, the cluster is a sort of battlefield, since the frequent changes in 
vertical input-output and the relationships between horizontal organizations generate 
a need for change. 
Clusters cause the change of innovation policies, generating policies suitable for cluster 
construction, thus functioning as catalyst in creating a more suitable environment for their 
own formation. 
Accordingly, the preferred definition of clusters is: the dynamically changing vertical and 
horizontal cooperation of geographically proximate organizations, involving an enterprise 
support infrastructure, with shared developmental vision for business growth of the 
clusterized organizations, based on competition and cooperation in a specific market field. 
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Besides the value chain method, cluster functioning has been described by several other 
theories as well. European Union experts differentiate four schools when defining the idea 
of clusters (Lengyel 2001):
– Italian school: the school’s central category is composed of industrial districts, 
which are formed due to the geographical concentration of small and medium-sized 
enterprises with similar activities. The concept can be traced back to Marshall, where 
externalities, trust, and social capital, all play an essential role. 
– Californian school: emphasis is placed on networks of production relations formed 
due to vertical disintegration. The main purpose of network functioning is lowering 
the costs. 
– Scandinavian school: in the concept of cluster, only locally applicable knowledge, 
especially non codified, hidden knowledge and the subsequently formed innovations 
play essential roles. 
– Regional cluster: All the previously mentioned three schools described the cluster as 
a locally bound process which is rooted in the social systems of a particular region. 
The main emphasis was placed on locally-specific elements. Porter, however, did not 
examine regional economy and clusters, but the competitive benefits at the company 
level and their resources. In his case, clusters are based on the cooperation and flow of 
information between companies and institutes. Several models were worked out for 
clusters, a general feature of which is that the competing key companies of a particular 
field are in the centre, they form the „core” of the cluster with their networks, 
importers and branch institutes. Due to the vast global market, these companies are 
able to grow dynamically and expand their production rapidly. The key companies 
(core companies) are independent companies. Often there is no formal cooperation 
between them (e.g. between German car factories), but they firmly compete with 
each other. Key companies rely on their business partners, associated industries and 
supporting (non business) institutes (Lengyel 2003). A cluster is only effective if the 
background institutes are geographically concentrated around the „core”. Porter’s 
value chain concept appeared in the mid 1980’s theoretical background. It is based 
on the recognition that the success of a company is primarily determined by the 
effectiveness in which it can mobilize its resources in the interest of increasing the 
value of its services, products and added value. The value chain model handles the 
enterprise based on the three following criteria (Friedman 2004):
– What interlinked activities result in marketing of the product
– How do these activities contribute to the added value of the end product
– How much of the company’s resources do these activities require.
The value chain model breaks down the enterprise, based on its strategically important 
activities, so that we can better understand the process of how expenses are formed 
and discover the possible differences present. The value chain method has already been 
used to describe cluster functioning in general cases, not specifically in biotechnology 
and in the pharmaceutical industry. The value chain method, however, is often used in 
the pharmaceutical industry, but it defines the R+D phases and the sequence of tasks to 
complete instead of the motivation for cooperation.  
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The value chain model can be easily applied for biotech cluster functioning because:
•	 it is commonly used in the pharmaceutical industry
•	 it can be easily interpreted
•	 it can be easily completed, modified and made dynamic
Cooperating organizations must reach activities respective to the holistic6 model of the 
innovation in all necessary areas, not one by one, but together. Thus organization within 
the cluster must produce some novelty at each appropriate step of the value chain. This is 
not difficult since each organization is capable of most efficiently undertaking the task best 
suited to its capacities and goals. Thus there is no need for organizations to take the often 
repetitive steps of learning a new skill, as new organizations will step in to fill the gaps (in 
well a functioning economy, in a well functioning cluster). As we can see, in the tables in the 
middle of the figure, the method for acquiring new information is divided in two: within 
the company and through the use of an outside source.
By applying the value chain model, we can show and explain how the organizations are 
built on each other. The value chain model is derived from the linear model of innovation, 
thus there is no feedback in the model. In practice we see strong feedback, as even the 
sales at the end of the chain have a strong influence on the basic research. For example, on 
market gaps, or the perspectives found by companies in charge of end marketing and sales 
feedback to basic research by determining the general directions of projects. In the model, 
basic research is an especially important linearly sequential process which does not take 
place in practice. Even though only projects that reach the market are included in the model, 
it is still not complete, as it does not allow for selection. However, the value chain model 
is good for describing the cooperation between the organizations, since different tasks can 
be completed by different organizations, as seen in the value chain in figures 4. and 5. A 
further weakness in the model is that, due to the lack of feedback, it regards the marketed 
product as final. Thus, it cannot change, since it is no longer in contact with the product 
development unit, thus assuming the prolonged balance of supply and demand, with only 
quantitative changes in demand. Regardless of these deficiencies, the value chain model is 
suitable for displaying cooperation between organizations, and it creates opportunities for 
further improvement and eliminating deficiencies. 
According to the value chain, the sequential technical and economic steps lead to new 
products. The value of projects, based on this value, is continuously increasing (according 
to greater added value). The end value can be calculated easily from the last step, as the 
product of market sales, price, and quantity. If we know the expenses incurred during 
previous steps, we can also easily calculate the profit from this value.
The value chain applies to the pharmaceutical industry relatively well, since a marketed 
pharmaceutical product cannot be changed without consequences. If there is a significant 
change in the product, there are consequences in registration, possibly clinical research, 
which require significant time and resources. In many cases changing the product is not 
profitable, even if it could be produced less expensively in better quality. Naturally there is 
feedback here as well, but in most cases the new innovation will only be used in the next 
generation of the product. 
6 The Holistic model shows clearly that innovation can occur throughout a company’s operations, triggered in some 
cases by new knowledge, but in other cases by an opportunity to fulfill a market need.
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Figure 4.:
The pharma value chain (the author)
a. Defining specific goals, therapeutic areas, or molecules with specific effects, possibly 
the definition of specific molecules in basic research. Overview is necessary during 
project operation. Furthermore, research topics are verified and new phases are 
planned.
b. By using the basic research results obtained during the development phase, problems 
involving increasing quantity are undertaken. Some production processes start to 
appear in this phase, related to pre-clinical testing, as well as for Phase I, Phase II and 
Phase III tests. Clinical tests also take place during this phase. 
c. Registration and accreditation take place, according to the test result of the previous 
phase.
d. Market production takes place during the production phase.
e. During the last step, in addition to sales, Phase IV, testing is completed, which is 
essentially product monitoring.
Costs and risks are divided automatically by cooperation and division of labor. Since, 
for pharmaceutical companies, it is most effective to find the most knowledgeable, most 
experienced “knowledge importers” in a given field, it will not be viable to develop the in-
house knowledge base completely, thus reducing time and cost requirements. Successful 
projects and industrially applicable results are selected, forming the basis of cooperation. 
Thus projects cost less altogether, since fewer resources are needed for determining which 
research result will be viable at an industrial level. Since this way there is no need for 
producing the research result in-house, smaller companies, or academic institutions, cannot 
contribute significantly to project funds. Most often projects are sold after verification of 
“proof of concept,” but up until then, the cooperation costs significantly less. 
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require significant time and resources. In many cases changing the product is not profitable, 
even if it could be produced less expensively in better quality. Naturally there is feedback 
here as well, but in most cases the new innovation will only be used in the next generation of 
the product.  
 
Figure 4.: The pharma value chain (the author) 
a. Defining specific goals, th rapeutic areas, or molecule  w th sp ific effects, 
possibly he de inition of specific molecules in basic research. Overview is necessary 
during project operation. Furthermore, research topics are verified and new ph s s 
are planned. 
b. By using the basic research results obtaine  during the development phase, problems 
involving increasing quantity are undertaken. Some production proce ses start to 
a pear in this phase, related to pre-clinical esting, as well as for Phase I, Phase II 
and Phase III tests. Clinical tests lso take place during thi  phase.  
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Figure 5:
Pharma value chain with organizations (the author)
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The value chain and (the absence of) a looped dynamism 
As I have stated earlier, the value chain model was derived from the linear model of 
innovation. Thus there is no feedback in the model, which therefore does not reflect reality 
well. In practice, we see strong feedback, since even sales at the end of the value chain can 
have strong influence on basic research.  
    Taking all these deficiencies into account, figures 4. and 5. can be completed by the 
addition of the feedback, thus displaying the division of labor and the progression of projects 
accurately (figure 6.). 
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130 Dávid Domonkos
The value chain and (the absence of) a looped dynamism
As I have stated earlier, the value chain model was derived from the linear model of 
innovation. Thus there is no feedback in the model, which therefore does not reflect reality 
well. In practice, we see strong feedback, since even sales at the end of the value chain can 
have strong influence on basic research. 
Taking all these deficiencies into account, figures 4. and 5. can be completed by the 
addition of the feedback, thus displaying the division of labor and the progression of 
projects accurately (figure 6.).
Figure 6.:
Pharma value chain with feedbacks  (the author)
All the feedback displayed on the figure is based on personal experience.
By adding these modifications, it is possible to describe the operation of clusters using 
the value chain model. It contains the dynamism of clusters and the interaction of different 
organizations and activities.
Summary
As we have seen in biotechnology, just as in other rapidly evolving branches of industry, 
changes are very fast; the increase of knowledge is very steep. Since this industry is a very 
high-risk (“high risk – high benefit”) industry, and since R+D phases may require several 
hundred million dollars, the participants seek to minimize and share the risks through 
cooperation. 
There are several theories that describe the motivations for cooperation. I used the value 
chain model, which is popular in the pharmaceutical industry, to describe the operation 
of clusters. The problem with this model is that it is static. The feedback, so characteristic 
in biotechnology, is missing. I completed this value chain approach, based mostly on my 
practical experience.
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    By adding these modifications, it is possible to describe the operation of clusters using the 
value chain model. It contains the dynamism of clusters and the interaction of different 
organizations a d activities. 
Summary 
As we have seen in biotechnology, just as in other rapidly evolving branches of industry, 
changes are very fast; the increase of knowledge is very steep. Since this industry is a very 
high-risk (“high risk – high benefit”) industry, and since R+D phases may require several 
hundred million dollars, the participants seek to minimize and share the risks through 
cooperation.  
There are several theories that describe the motivations for cooperation. I used the value chain 
model, which is popular in the pharmaceutical industry, to describe the operation of clusters. 
The problem with this model is that it is static. The feedback, so characteristic in 
biotechnology, is missing. I completed this value chain approach, based mostly on my 
practical experience. 
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